title: Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells.
abstract: The deviant poly(A) signal of hepatitis B virus (HBV) not only controls the formation of the 3' end of all the viral RNA, but is also crucial for HBV replication. Hence, a cis-releasing hammerhead ribozyme (RzA) targeted to the poly(A) signal region of HBV subtype adr was investigated for its antiviral effects. In vitro, RzA cleaved HBV RNA at its target site up to 70%, while the disabled ribozyme (dRzA), which had a one-base mutation in the catalytic site, did not cleave the target RNA at all. When the ribozymes were cotransfected into HepG2 cells with the HBV genome-containing plasmid p3.6II, the wild-type ribozyme RzA could effectively decrease HBV RNA levels and inhibit HBV replication, whereas its disabled form, dRzA, had much weaker effects, indicating that the active catalytic domain of the hammerhead ribozyme could markedly increase the extent of antisense-mediated inhibition. In addition, there was a gradient of effectiveness: the higher the amount of released ribozyme, the more the reduction in target HBV RNA in cells as well as progeny DNA reduction. These results suggest the possibility of the hammerhead ribozyme RzA to be used for the gene therapy of HBV infection.
authors.affiliation: Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.
authors.forename: Y
authors.initials: Y
authors.lastname: Feng
authors.forename: Y Y
authors.initials: YY
authors.lastname: Kong
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: G R
authors.initials: GR
authors.lastname: Qi
mesh_terms: D000998:Antiviral Agents / Q000378:metabolism / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular; D002999:Clone Cells; D004305:Dose-Response Relationship, Drug; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology; D011061:Poly A / Q000235:genetics; D021382:Protein Sorting Signals / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D016337:RNA, Catalytic / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology*; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D021382:Protein Sorting Signals; D016337:RNA, Catalytic; D012367:RNA, Viral; C427204:hammerhead ribozyme; D011061:Poly A